This study is strengthened by its large sample size, derived from a high-quality randomized folic acid clinical trial that for the first time incorporated MTHFR C677T genotypes in the randomization.2 We comprehensively analyzed the prospective association between platelet activation parameters (PCT, PLT, MPV, and PDW) and the first stroke risk in patients with MTHFR C677T genotype, and determined that PCT assessment was the most useful. Here, MTHFR is linked to stroke disorder.